Stock Events

Stock Events

Ribomic 

¥90
5
-¥1-1.1% Today

Statistics

Day High
95
Day Low
88
52W High
141
52W Low
72
Volume
1,513,800
Avg. Volume
2,745,098
Mkt Cap
4.62B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-6.37
-5.76
-5.16
-4.55
Expected EPS
N/A
Actual EPS
N/A

Financials

-48,359.71%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.21MRevenue
-2.04BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4591.TSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics, directly competing with Ribomic's RNA-based drug development.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals, Inc. specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them, similar to Ribomic's approach.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is known for its mRNA technology platform, competing in the broader RNA-based therapeutic and vaccine development market.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, placing it in competition with RNA-focused companies like Ribomic.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing technologies, including CRISPR/Cas9, competing in the genetic medicine space alongside RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. is a leading genome editing company, which, while focusing on CRISPR technology, competes in the broader market of genetic therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. is a pioneer in CRISPR/Cas9 technology for gene editing, indirectly competing with RNA therapy developers by offering alternative genetic treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. employs a diverse genome editing platform that includes zinc finger nuclease (ZFN) technology, competing in gene and cell therapy, including RNA-based approaches.

About

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, achondroplasia, osteoarthritis, diabetic retinopathy, pulmonary arterial hypertension, osteosclerosis, and fibrosis, as well as age-related macular degeneration. Ribomic Inc. has a joint research and development agreement with ASKA Pharmaceutical Co., Ltd. for drug discovery research and development targeting specific hormone receptors. The company was incorporated in 2003 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Yoshikazu Nakamura
Employees
26
Country
JP
ISIN
JP3974850004

Listings

TSE
JP
4591.TSE

0 Comments

Share your thoughts

FAQ

What is Ribomic stock price today?▼
The current price of 4591.TSE is ¥90 JPY — it has decreased by -1.1% in the past 24 hours. Watch Ribomic stock price performance more closely on the chart.
What is Ribomic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ribomic stocks are traded under the ticker 4591.TSE.
Is Ribomic stock price growing?▼
4591.TSE stock has fallen by -5.26% compared to the previous week, the month change is a +4.65% rise, over the last year Ribomic has showed a -4.26% decrease.
What is Ribomic market cap?▼
Today Ribomic has the market capitalization of 4.62B
When is the next Ribomic earnings date?▼
Ribomic is going to release the next earnings report on May 19, 2026.
What were Ribomic earnings last quarter?▼
4591.TSE earnings for the last quarter are -4.55 JPY per share, whereas the estimation was N/A JPY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is Ribomic revenue for the last year?▼
Ribomic revenue for the last year amounts to 4.21M JPY.
What is Ribomic net income for the last year?▼
4591.TSE net income for the last year is -2.04B JPY.
How many employees does Ribomic have?▼
As of April 02, 2026, the company has 26 employees.
In which sector is Ribomic located?▼
Ribomic operates in the Healthcare sector.
When did Ribomic complete a stock split?▼
Ribomic has not had any recent stock splits.
Where is Ribomic headquartered?▼
Ribomic is headquartered in Tokyo, JP.